To improve cancer patient safety and treatment quality, DOSIsoft, leading provider of patient-specific software solutions in Radiation Oncology & Nuclear Medicine, distributed in more than 60 countries, announces that it has signed a development and commercialization agreement (license) with the Assistance Publique – Hôpitaux de Paris (AP-HP) for a Radioiodine theranostic solution applied to benign thyroid diseases named "QUANTHYR".
« QUANTHYR »: an innovation patented* for the personalized treatment of hyperthyroidism diseases
Many years of research conducted by Professor Jérôme Clerc, head of nuclear medicine department at Cochin hospital - AP-HP, have resulted in the creation of “QUANTHYR" solution, which aims to optimize the diagnostic and prognostic performance of thyroid scintigraphy images. This application simplifies the personalization of iodine-131 prescriptions, making them individualized from a clinical perspective and optimized from a dosimetric perspective, regardless of the type of hyperthyroidism.
For the first time, "QUANTHYR" enables direct visualization of the dose distribution in the thyroid, corresponding to the prescribed iodine-131 activities (in this case, 296 MBq prescribed, with an average absorbed dose of 100 Gy).
"QUANTHYR" facilitates the Iodine-131 radiopharmaceutical prescription process and helps limit the level of administered activity, which is required in radiation protection. Finally, the quantified data generated by the imaging software will pave the way for a more precise classification of the different types of hyperthyroidism, powered by AI (neural networks).
Under the protection and value-added proposal from the Transfer and Innovation Division team within the AP-HP Clinical Research and Innovation Department, the innovation is based on two "prototype" software programs used exclusively for research purposes: the first is dedicated to imaging & diagnosis and the second is focused on individualized dosimetry therapy.
In 2021, "QUANTHYR" was also awarded in the first session of the "Booster Innovation” call for projects launched by AP-HP, aimed at professionals. This initiative sought to develop and industrialize an integrated solution for the personalized treatment of hyperthyroidism.
DOSIsoft & AP-HP: a close collaboration on technology transfer and commercial development of “QUANTHYR”
Leveraging its expertise in medical imaging and dosimetry acquired over more than 20 years, DOSIsoft was initially selected as a specialized software provider and subsequently as a preferred partner to support AP-HP in the successful development, clinical evaluation and commercialization of the new “QUANTHYR” module.
